6th November 2026
ALD Worm Lab visit
Our CEO, Sara, visited the adrenoleukodystrophy (ALD) worm models being used in a drug repurposing research project at the MRC Laboratory of Medical Sciences.
Stay up to date
6th November 2026
Our CEO, Sara, visited the adrenoleukodystrophy (ALD) worm models being used in a drug repurposing research project at the MRC Laboratory of Medical Sciences.
26th October 2026
Our Research Summary includes information about recent leukodystrophy research and clinical trials, including article summaries and direct links to websites and articles.
20th October 2026
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD).
28th September 2026
Our Research Summary includes information about recent leukodystrophy research and clinical trials, including article summaries and direct links to websites and articles.
8th September 2026
7th September 2026
28th August 2026
A research team at King’s College London carrying out a study looking at how social care support could be improved for children with life-limiting conditions and their families.
27th August 2026
Our Research Summary includes information about recent leukodystrophy research and clinical trials, including article summaries and direct links to websites and articles.
17th August 2026
27th July 2026
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients
20th July 2026
We’re pleased to share Genetic Alliance UK’s research report, Independent Evaluation of the Generation Study: Views of support organisations.
17th July 2026
The APBD Research Foundation is conducting a survey of patients and caregivers to prepare their community for future clinical trials – referred to as “clinical trial readiness.”